Oligopeptide-177 is a 33-amino-acid-length synthetic peptide whose sequences repeat a fragment of the erythropoietin (EPO) glycoprotein. It is a non-erythropoietic erythropoietin-derived peptide.
EPO's primary function is the stimulation of blood red cell (erythrocyte) production. Still, it also has other functions, including promoting tissue regeneration and cell protection (preventing apoptosis, or cell self-destruction).
Scientific studies have shown that the topical application of a preparation containing human erythropoietin accelerates wound healing and skin regeneration. It supports new microvessel formation, enhancing the delivery of oxygen and nutrients to regenerating tissues, while also boosting growth factor generation, resulting in skin recovery without the formation of scar tissue.
Thanks to a specific structure (sequence), Oligopeptide-177 does not affect hematopoietic (blood cell production) processes but keeps other beneficial functions that are in demand in modern skincare applications. After topical application, it can bind to a specific receptor CD90 on skin keratinocytes and fibroblasts, promoting skin regeneration, renewal, and wound healing.In clinical trials, Oligopeptide-177 exhibited significant beneficial effects against signs of skin aging, acne, and UV-induced irritation. It is one of the active ingredients in the patented complex TFC8® (Trigger Factor Complex) by Augustinus Bader, where it plays a significant role.
